Robert H. Getzenberg

home / authors / robert-h-getzenberg

Articles

7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 Inhibitor

7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 Inhibitor

Adam M. Brufsky, MD, PhD;Hannah M. Linden, MD;Hope S. Rugo, MD;Joyce A. O’Shaughnessy;Robert H. Getzenberg;K. Gary Barnette;Domingo Rodriguez;Mitchell Steiner;Erica L. Mayer, MD, MPH
April 18th 2022
8 TiP Randomized, Multicenter, Phase 3 Study to Evaluate the Combination of Enobosarm and Abemaciclib Compared With Estrogen-Blocking Agent for the Second-Line Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Have Previously Received Palbociclib and an Estrogen-Blocking Agent Combination Therapy

8 TiP Randomized, Multicenter, Phase 3 Study to Evaluate the Combination of Enobosarm and Abemaciclib Compared With Estrogen-Blocking Agent for the Second-Line Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Have Previously Received Palbociclib and an Estrogen-Blocking Agent Combination Therapy

Elgene Lim, MBBS, FRACP, PhD;Adam M. Brufsky, MD, PhD;Hope S. Rugo, MD;Charles L. Vogel, MD, FACP;Joyce A. O’Shaughnessy;Robert H. Getzenberg;K. Gary Barnette;Domingo Rodriguez;Mitchell Steiner;Hannah M. Linden, MD
April 18th 2022

Latest Updated Articles

OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
45-Year-Old Female With Gross Hematuria Post Partial Nephrectomy
Published: March 1st 2018 | Updated: July 27th 2024
45-Year-Old Female With Gross Hematuria Post Partial Nephrectomy
Neonate With a Soft, Yellowish-Colored Plaque on the Temple
Published: July 16th 2011 | Updated: July 27th 2024
Neonate With a Soft, Yellowish-Colored Plaque on the Temple
A 54-Year-Old Woman Notes the Abundant Development of Nonpigmented Hair on Her Ears and Nose
Published: May 12th 2012 | Updated: July 27th 2024
A 54-Year-Old Woman Notes the Abundant Development of Nonpigmented Hair on Her Ears and Nose
Patient With History of COPD Presents With Abdominal Pain
Published: December 1st 2016 | Updated: July 27th 2024
Patient With History of COPD Presents With Abdominal Pain